Trazimera Kit
NDC Package 0069-0305-01
Package Information
Trazimera (trastuzumab-qyyp) kits is none. This formulation utilizes a kit delivery system. Marketed by Pfizer Laboratories Div Pfizer Inc, this product is identified by NDC 0069-0305 and is authorized under FDA application BLA761081.
Identification & Billing
- RxCUI: 2280732 - trastuzumab-qyyp 420 MG in 20 ML Injectable Solution
- RxCUI: 2280732 - trastuzumab-qyyp 21 MG/ML Injectable Solution
- RxCUI: 2280732 - trastuzumab-qyyp 420 MG per 20 ML Injectable Solution
- RxCUI: 2280737 - Trazimera 420 MG in 20 mL Injectable Solution
- RxCUI: 2280737 - trastuzumab-qyyp 21 MG/ML Injectable Solution [Trazimera]
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 0069 - Pfizer Laboratories Div Pfizer Inc
- 0069-0305 - Trazimera
- 0069-0305-01 - 1 KIT in 1 KIT * 20 mL in 1 VIAL, MULTI-DOSE (0069-0306-01) * 20 mL in 1 VIAL (0069-0307-01)
- 0069-0305 - Trazimera
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Billing & HCPCS Mapping
To facilitate insurance claims and reimbursement, this drug package is mapped to specific HCPCS administrative codes. This crosswalk aligns clinical data with the billing standards used in ASP (Average Sales Price), AWP, and OPPS payment systems. Use the cards below to identify the correct billable units for provider claims.
Note for Medical Coders: These mappings are synthesized from various CMS datasets including OPPS, PrEP, and DAC (Data Analysis and Coding) contractors. Always confirm unit conversions against the current quarter's pricing files before final submission.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 0069-0305-01 identifies a specific commercial package of 1 kit in 1 kit * 20 ml in 1 vial, multi-dose (0069-0306-01) * 20 ml in 1 vial (0069-0307-01) of Trazimera, a human prescription drug labeled by Pfizer Laboratories Div Pfizer Inc. This kit is formulated for use and contains as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Pfizer Laboratories Div Pfizer Inc on February 24, 2020. The current certification is valid through December 31, 2027.
How is this Pfizer Laboratories Div Pfizer Inc product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 00069030501. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Labeler segment to maintain the 5-4-2 structure.